Allergan and AstraZeneca team up to develop ATM-AVI
Allergan and AstraZeneca are to develop and commercialise ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam. With ATM-AVI they present a new treatment option for patients with MBL-producing pathogens.
Click on this link for more information.
